Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy Study of Travoprost APS Versus TRAVATAN

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Alcon Research
ClinicalTrials.gov Identifier:
NCT00848536
First received: February 19, 2009
Last updated: April 4, 2012
Last verified: April 2012
Results First Received: February 14, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Investigator);   Primary Purpose: Treatment
Conditions: Open Angle Glaucoma
Ocular Hypertension
Interventions: Drug: Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution
Drug: Travoprost 0.004% (BAK-preserved) Eye Drops, Solution

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients were recruited from 30 study centers: 8 in the US, 6 in Mexico, 2 in Brazil, 4 in India, 2 in Australia, 2 in New Zealand, 2 in Latvia, and a single site in each: Taiwan, France, Belgium, and Italy.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
TRAVATAN APS One drop once daily in the evening for 3 months
TRAVATAN One drop once daily in the evening for 3 months

Participant Flow:   Overall Study
    TRAVATAN APS   TRAVATAN
STARTED   185   186 
COMPLETED   181   179 
NOT COMPLETED   4   7 
Adverse Event                2                2 
Withdrawal by Subject                0                1 
Protocol Violation                0                1 
Noncompliance                1                0 
Inadequate Control of IOP                1                1 
Patient Moved                0                2 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
TRAVATAN APS One drop once daily in the evening for 3 months
TRAVATAN One drop once daily in the evening for 3 months
Total Total of all reporting groups

Baseline Measures
   TRAVATAN APS   TRAVATAN   Total 
Overall Participants Analyzed 
[Units: Participants]
 185   186   371 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   94   109   203 
>=65 years   91   77   168 
Gender 
[Units: Participants]
     
Female   112   115   227 
Male   73   71   144 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Mean Intraocular Pressure at 9:00 am   [ Time Frame: 3 months (measured at 9:00 am) ]

2.  Primary:   Mean Intraocular Pressure at 11:00 am   [ Time Frame: 3 months (measured at 11:00 am) ]

3.  Primary:   Mean Intraocular Pressure at 4:00 pm   [ Time Frame: 3 months (measured at 4:00 pm) ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Director Alcon Clinical
Organization: Alcon Research, Ltd.
phone: 888.451.3937 or 817.568.6725



Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT00848536     History of Changes
Other Study ID Numbers: C-08-40
2008-006027-31 ( EudraCT Number )
Study First Received: February 19, 2009
Results First Received: February 14, 2011
Last Updated: April 4, 2012
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board